TW200738228A - Neramexane modified release matrix tablet - Google Patents

Neramexane modified release matrix tablet

Info

Publication number: TW200738228A
Authority: TW; Taiwan
Prior art keywords: modified release; neramexane; dosage forms; release matrix; dementia
Prior art date: 2005-11-30

Application number

TW095144015A

Other languages

English (en)

Inventor

Bernhard Hauptmeier

Andreas Becker

Original Assignee

Merz Pharma Gmbh & Co Kgaa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-30

Filing date

2006-11-28

Publication date

2007-10-16

2006-11-28 Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa

2007-10-16 Publication of TW200738228A publication Critical patent/TW200738228A/zh

Links

OGZQTTHDGQBLBT-UHFFFAOYSA-N neramexane Chemical compound CC1(C)CC(C)(C)CC(C)(N)C1 OGZQTTHDGQBLBT-UHFFFAOYSA-N 0.000 title abstract 3
229950004543 neramexane Drugs 0.000 title abstract 3
239000013563 matrix tablet Substances 0.000 title 1
239000002552 dosage form Substances 0.000 abstract 3
208000024827 Alzheimer disease Diseases 0.000 abstract 2
208000004296 neuralgia Diseases 0.000 abstract 2
208000021722 neuropathic pain Diseases 0.000 abstract 2
238000011340 continuous therapy Methods 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
230000000873 masking effect Effects 0.000 abstract 1
239000011159 matrix material Substances 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000036470 plasma concentration Effects 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Child & Adolescent Psychology (AREA)
Diabetes (AREA)
Hematology (AREA)
Nutrition Science (AREA)
Obesity (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Psychology (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Dermatology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

TW095144015A 2005-11-30 2006-11-28 Neramexane modified release matrix tablet TW200738228A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US74097505P	2005-11-30	2005-11-30

Publications (1)

Publication Number	Publication Date
TW200738228A true TW200738228A (en)	2007-10-16

Family

ID=37698309

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW095144015A TW200738228A (en)	2005-11-30	2006-11-28	Neramexane modified release matrix tablet

Country Status (14)

Country	Link
US (1)	US20070141148A1 (zh)
EP (1)	EP1959941A1 (zh)
JP (2)	JP5276989B2 (zh)
KR (1)	KR101084832B1 (zh)
CN (1)	CN101300001B (zh)
AR (1)	AR056824A1 (zh)
AU (1)	AU2006319411B8 (zh)
BR (1)	BRPI0619384A2 (zh)
CA (1)	CA2624589C (zh)
IL (1)	IL191578A0 (zh)
RU (1)	RU2422135C2 (zh)
TW (1)	TW200738228A (zh)
WO (1)	WO2007062815A1 (zh)
ZA (1)	ZA200803172B (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200916091A (en) *	2007-06-08	2009-04-16	Merz Pharma Gmbh & Amp Co Kgaa	Neramexane for the treatment of nystagmus
RU2452476C2 (ru) *	2007-09-12	2012-06-10	Мерц Фарма Гмбх Унд Ко. Кгаа	Производные 1-аминоалкилциклогексана для лечения и предупреждения потери слуха
US20110086916A1 (en)	2007-09-12	2011-04-14	Merz Pharma Gmbh & Co. Kgaa	Interval therapy for the treatment of tinnitus
TW201010691A (en) *	2008-06-12	2010-03-16	Merz Pharma Gmbh & Co Kgaa	1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
TW201006463A (en) *	2008-06-26	2010-02-16	Merz Pharma Gmbh & Co Kgaa	Pharmaceutical compositions comprising aminocyclohexane derivatives
JP2012501304A (ja) *	2008-09-10	2012-01-19	メルツ・ファルマ・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー・コマンデイトゲゼルシヤフト・アウフ・アクティーン	耳鳴における認知障害を治療するための１−アミノ−アルキルシクロヘキサン誘導体
MX2011006353A (es) *	2008-12-19	2011-07-13	Merz Pharma Gmbh & Co Kgaa	Derivados de 1-amino-alquilciclohexano para el tratamiento de enfermedades mediadas por mastocitos.
TWI432188B (zh)	2008-12-19	2014-04-01	Merz Pharma Gmbh & Co Kgaa	供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
US8784847B2 (en)	2009-04-17	2014-07-22	Merz Pharma Gmbh & Co. Kgaa	Synthesis of 1-amino-1,3,3,5,5,-cyclohexane mesylate
CA2765611A1 (en) *	2009-06-29	2011-01-06	Merz Pharma Gmbh & Co. Kgaa	Method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane
EP2448908B1 (en) *	2009-06-29	2013-09-18	Merz Pharma GmbH & Co. KGaA	Method of preparing neramexane
JP5738854B2 (ja) *	2009-06-29	2015-06-24	メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー	ネラメキサンの製造方法
JP2013502427A (ja) *	2009-08-21	2013-01-24	ユニバーシティオブフロリダリサーチファンデーションインコーポレーティッド	アナバセイン化合物の制御放出製剤およびその使用
US20120202894A1 (en) *	2009-09-18	2012-08-09	Basf Se	Rapidly Soluble Solid Pharmaceutical Preparations Containing Amphiphilic Copolymers Based On Polyethers In Combination With Hydrophilic Polymers
US20110294890A1 (en) *	2010-05-28	2011-12-01	Merz Pharma Gmbh & Co. Kgaa	Neramexane for the treatment or prevention of inner ear disorders
JP2013528632A (ja)	2010-06-18	2013-07-11	メルツファーマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフトアウフアクティーン	１−アミノ−アルキルシクロヘキサン誘導体の局所用途のためのゲル製剤
JP2013529604A (ja) *	2010-06-24	2013-07-22	メルツファーマゲゼルシャフトミットベシュレンクテルハフツングウントコンパニーコマンディトゲゼルシャフトアウフアクティーン	ネラメキサン複数単位剤形
EP2621509A4 (en) *	2010-09-15	2016-08-03	Synergy Pharmaceuticals Inc	FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHOD OF USE
WO2012098000A1 (en)	2011-01-20	2012-07-26	Merz Pharma Gmbh & Co. Kgaa	Neramexane for the treatment or prevention of tinnitus related with stress or acute hearing loss
KR102290249B1 (ko) *	2013-06-12	2021-08-17	노파르티스 아게	변형 방출 제제
CN115697414A (zh) *	2020-06-03	2023-02-03	哥本哈根大学	Glp1r激动剂nmdar拮抗剂缀合物
CU24720B1 (es) *	2020-11-24	2024-10-09	Centro De Neurociencias De Cuba	Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer
CN115507773B (zh) *	2021-06-07	2025-02-18	广州视源电子科技股份有限公司	三维测量方法及系统
CA3239054A1 (en) *	2021-12-02	2023-06-08	Kobenhavns Universitet	Peptide-drug conjugates for treatment of neurodegenerative diseases

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3007387B2 (ja) *	1990-07-16	2000-02-07	エーザイ株式会社	徐放性製剤用基剤粉末
DE4443358A1 (de) *	1994-12-06	1996-06-13	Basf Ag	Depot-Arzneimittel
UA61962C2 (uk) *	1997-06-30	2003-12-15	Мерц Фарма Гмбх Унд Ко. Кгаа	Сполука 1-аміноалкілциклогексану, фармацевтична композиція на її основі та спосіб лікування
US8293277B2 (en) *	1998-10-01	2012-10-23	Alkermes Pharma Ireland Limited	Controlled-release nanoparticulate compositions
US20030050620A1 (en) *	2001-09-07	2003-03-13	Isa Odidi	Combinatorial type controlled release drug delivery device
TW200418527A (en) *	2002-10-31	2004-10-01	Alza Corp	Dosage form providing ascending release of liquid formulation
US7704528B2 (en) *	2003-05-05	2010-04-27	Isp Investments Inc.	Binder composition and method for processing poorly compressible drugs into tablets of predetermined hardness and friability
EP2260844A1 (en) *	2003-05-27	2010-12-15	Merz Pharma GmbH & Co. KGaA	Combination of an NMDA Receptor Antagonist and a Selective Serotonin Reuptake Inhibitor for the Treatment of Depression and other Mood Disorders
AU2004258751C1 (en) *	2003-07-28	2008-07-17	Merz Pharma Gmbh & Co. Kgaa	The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity
US20050123502A1 (en) *	2003-10-07	2005-06-09	Chan Shing Y.	Nicotine containing oral compositions
CN1870984A (zh) *	2003-10-22	2006-11-29	莫茨药物股份两合公司	1－氨基环己烷衍生物用于调节淀粉样病变中原纤维生成Aβ肽的沉积的用途
TW200531680A (en) *	2004-03-03	2005-10-01	Merz Pharma Gmbh & Co Kgaa	Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
BRPI0508743A (pt) *	2004-03-24	2008-01-22	Lupin Ltd	composição farmacêutica com uma liberação estendida de eritromicina ou um derivado da mesma, método para o uso de uma composição farmacêutica e processo para a preparação de uma composição farmacêutica
CA2569015A1 (en) *	2004-06-17	2006-01-26	Forest Laboratories, Inc.	Modified release formulation of memantine
US20060002999A1 (en) *	2004-06-17	2006-01-05	Forest Laboratories, Inc.	Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
US7619007B2 (en) *	2004-11-23	2009-11-17	Adamas Pharmaceuticals, Inc.	Method and composition for administering an NMDA receptor antagonist to a subject
EP1827385B1 (en) *	2004-11-23	2013-03-27	Adamas Pharmaceuticals, Inc.	Pharmaceutical composition comprising memantine in an extended dosage release form for use in the treatment of dementias
US8389578B2 (en) *	2004-11-24	2013-03-05	Adamas Pharmaceuticals, Inc	Composition and method for treating neurological disease
US20060205822A1 (en) *	2004-12-22	2006-09-14	Forest Laboratories, Inc.	1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect
EA013474B1 (ru) *	2005-06-16	2010-04-30	Форест Лэборэтериз, Инк.	Композиция в виде гранул с модифицированным и немедленным высвобождением мемантина

2006
- 2006-11-27 US US11/604,986 patent/US20070141148A1/en not_active Abandoned
- 2006-11-28 TW TW095144015A patent/TW200738228A/zh unknown
- 2006-11-29 RU RU2008126212/15A patent/RU2422135C2/ru not_active IP Right Cessation
- 2006-11-29 CA CA2624589A patent/CA2624589C/en not_active Expired - Fee Related
- 2006-11-29 WO PCT/EP2006/011438 patent/WO2007062815A1/en not_active Ceased
- 2006-11-29 CN CN2006800406697A patent/CN101300001B/zh not_active Expired - Fee Related
- 2006-11-29 BR BRPI0619384-6A patent/BRPI0619384A2/pt not_active IP Right Cessation
- 2006-11-29 JP JP2008542654A patent/JP5276989B2/ja not_active Expired - Fee Related
- 2006-11-29 KR KR1020087013022A patent/KR101084832B1/ko not_active Expired - Fee Related
- 2006-11-29 EP EP06818895A patent/EP1959941A1/en not_active Withdrawn
- 2006-11-29 AU AU2006319411A patent/AU2006319411B8/en not_active Ceased
- 2006-11-30 AR ARP060105301A patent/AR056824A1/es not_active Application Discontinuation
2008
- 2008-04-10 ZA ZA200803172A patent/ZA200803172B/xx unknown
- 2008-05-20 IL IL191578A patent/IL191578A0/en unknown
2013
- 2013-03-05 JP JP2013042711A patent/JP5745556B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN101300001A (zh)	2008-11-05
EP1959941A1 (en)	2008-08-27
RU2422135C2 (ru)	2011-06-27
IL191578A0 (en)	2008-12-29
ZA200803172B (en)	2009-03-25
JP5276989B2 (ja)	2013-08-28
AR056824A1 (es)	2007-10-24
JP2013136620A (ja)	2013-07-11
AU2006319411A1 (en)	2007-06-07
AU2006319411B8 (en)	2010-10-21
CN101300001B (zh)	2011-12-14
JP2009517420A (ja)	2009-04-30
CA2624589A1 (en)	2007-06-07
RU2008126212A (ru)	2010-01-10
CA2624589C (en)	2011-05-24
KR20080069218A (ko)	2008-07-25
AU2006319411B2 (en)	2010-09-16
KR101084832B1 (ko)	2011-11-21
US20070141148A1 (en)	2007-06-21
WO2007062815A1 (en)	2007-06-07
JP5745556B2 (ja)	2015-07-08
HK1124762A1 (zh)	2009-07-24
BRPI0619384A2 (pt)	2011-10-04

Publication	Publication Date	Title
TW200738228A (en)	2007-10-16	Neramexane modified release matrix tablet
CY1115484T1 (el)	2017-01-04	Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson
WO2008131056A3 (en)	2009-12-03	Sustained release monoeximic formulations of opioid and nonopioid analgesics
TW200626159A (en)	2006-08-01	Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor
WO2008021113A3 (en)	2008-08-14	Transdermal methods and systems for treating alzheimer's disease
WO2008131057A3 (en)	2009-12-03	Sustained release formulations of opioid and nonopioid analgesics
WO2003005968A3 (en)	2003-10-16	Dual release levodopa ethyl ester and decarboxylase inhibitor with immediate release levodopa
EP1933833B8 (en)	2011-09-14	Therapy for the treatment of overactive bladder
SI1546127T1 (sl)	2008-08-31	Novi pirimidinamidni derivati in njihova uporaba
WO2008142572A3 (en)	2009-02-12	Controlled release tablet formulation containing magnesium aluminometasilicate
UA104988C2 (uk)	2014-04-10	Похідні піроніндолу та спосіб їх отримання
MXPA05012810A (es)	2006-02-13	Formas de dosis oral de memantina.
PT2205279E (pt)	2011-07-11	Associação farmacêutica de aliscireno e valsartan
MX2011011459A (es)	2011-11-18	Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
MXPA03009849A (es)	2004-05-24	Uso de azitromicina para la fabricacion de un medicamento para el tratamiento de enfermedades inflamatorias no infecciosas.
MXPA05012358A (es)	2006-02-02	Combinacion farmaceutica que comprende modafinilo y otra droga.
PL367464A1 (en)	2005-02-21	Pharmaceutical composition comprising lumiracoxib
GB2446341A (en)	2008-08-06	Method and system for transdermal drug delivery
SG158863A1 (en)	2010-02-26	Intravenous formulations of pde-5 inhibitors
MX2025014320A (es)	2026-01-07	Compuestos nitrogenados aromaticos, metodos de preparacion y usos medicinales
WO2006108692A3 (en)	2007-12-06	Dosage form for oral administration of a vitamin
BRPI0513598A (pt)	2008-05-13	formas de dosagem em comprimidos revestidos de liberação entérica
PL1656131T3 (pl)	2011-07-29	Zastosowanie betainy w leczeniu chromania przestankowego
MXPA05008843A (es)	2005-10-18	Sistema terapeutico que comprende amoxicilina y acido clavulanico.
TW200616644A (en)	2006-06-01	Medicine for prevention or treatment of diabetes